Identification
- Summary
Calcium gluconate is an ingredient found in a variety of supplements and vitamins, and is used to lower potassium in the blood or treat magnesium poisoning.
- Generic Name
- Calcium gluconate
- DrugBank Accession Number
- DB11126
- Background
Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only. Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate. Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Calcium gluconate (DB11126)
- Weight
- Average: 430.372
Monoisotopic: 430.0635463 - Chemical Formula
- C12H22CaO14
- Synonyms
- Calcarea gluconica
- Calcii gluconas
- Calcio gluconato
- Calcium di-gluconate
- Calcium gluconate
- Calcium gluconate anhydrous
- Calcium gluconate, anhydrous
- D-gluconic acid, calcium salt (2:1)
- External IDs
- E-578
- INS NO.578
- INS-578
Pharmacology
- Indication
Oral calcium salts are used as dietary supplemental therapy for person who may not get enough calcium in their regular diet. Calcium gluconate is used as a cardioprotective agent in high blood potassium. Calcium gluconate is the antidote for magnesium sulfate toxicity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Bone and tooth decay Combination Product in combination with: Calcium citrate (DB11093), Calcium carbonate (DB06724), Cholecalciferol (DB00169) ••• ••• •••••••• •••••• ••••••••• ••••• Used in combination to maintain Bone and tooth growth Combination Product in combination with: Cholecalciferol (DB00169), Calcium carbonate (DB06724), Calcium citrate (DB11093) ••• ••• Used in combination to prevent Calcium deficiency Combination Product in combination with: Cholecalciferol (DB00169), Calcium Phosphate (DB11348), Calcium lactate (DB13231) •••••••••••• ••••••••••••• •••••• Used in combination to prevent Calcium deficiency Combination Product in combination with: Cholecalciferol (DB00169), Calcium lactate (DB13231), Calcium Phosphate (DB11348) •••••••••••• ••••••••• •••••• Used in combination to treat Hypocalcemia Combination Product in combination with: Calcium levulinate (DB13800) •••••••••••• •••••••••• ••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Calcium Gluconate is the gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers.
- Mechanism of action
Calcium is essential for the functional integrity of the nervous, muscular, and skeletal systems. It plays a role in normal cardiac function, renal function, respiration, blood coagulation, and cell membrane and capillary permeability. Also, calcium helps to regulate the release and storage of neurotransmitters and hormones, the uptake and binding of amino acids, absorption of vitamin B 12, and gastrin secretion. The major fraction (99%) of calcium is in the skeletal structure primarily as hydroxyapatite, Ca 10(PO 4) 6(OH) 2; small amounts of calcium carbonate and amorphous calcium phosphates are also present. The calcium of bone is in a constant exchange with the calcium of plasma. Since the metabolic functions of calcium are essential for life, when there is a disturbance in the calcium balance because of dietary deficiency or other causes, the stores of calcium in bone may be depleted to fill the body's more acute needs. Therefore, on a chronic basis, normal mineralization of bone depends on adequate amounts of total body calcium.
- Absorption
Approximately one-fifth to one-third of orally administered calcium is absorbed in the small intestine, depending on presence of vitamin D metabolites, pH in lumen, and on dietary factors, such as calcium binding to fiber or phytates. Calcium absorption is increased when a calcium deficiency is present or when a patient is on a low-calcium diet. In patients with achlorhydria or hypochlorhydria, calcium absorption, especially with the carbonate salt, may be reduced.
- Volume of distribution
Not available
- Protein binding
Moderate, approximately 45% in plasma.
- Metabolism
Calcium gluconate does not require hepatic metabolism for the release of Ca++ and is as effective as calcium chloride in treating ionic hypocalcemia in the absence of hepatic function.
- Route of elimination
Renal (20%) - The amount excreted in the urine varies with degree of calcium absorption and whether there is excessive bone loss or failure of renal conservation. Fecal (80%) - Consists mainly of nonabsorbed calcium, with only a small amount of endogenous fecal calcium excreted.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Infants : LDLo (Intramuscular ) : 10gm/kg ; Effects - Brain and coverings : meningeal changes Infants : TDLo ( Intramuscular ) : 143 mg/kg ; Effects - Dermatits Mouse: LD50 ( intravenous ) : 950mg/kg Mouse : LDLo (Oral ) : 10gm/kg
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium gluconate. Acetyldigitoxin Calcium gluconate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate. Alfacalcidol The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Calcium gluconate. Amiodarone The therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium gluconate. - Food Interactions
- Take with a full glass of water.
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Calcium gluconate monohydrate CZN0MI5R31 66905-23-5 XLNFVCRGJZBQGX-XRDLMGPZSA-L - Active Moieties
Name Kind UNII CAS InChI Key Calcium unknown SY7Q814VUP 7440-70-2 OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium cation ionic 2M83C4R6ZB 14127-61-8 BHPQYMZQTOCNFJ-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 2% Calcium Gluconate In Sodium Chloride Injection Solution 20 mg / mL Intravenous Fresenius Kabi Not applicable Not applicable Canada 
Calcium Gluconate Injection, solution 98 mg/1mL Intravenous Fresenius Kabi USA, LLC 2017-06-15 Not applicable US 
Calcium Gluconate Injection, solution 94 mg/1mL Intravenous Remedy Repack 2015-06-19 2017-07-25 US Calcium Gluconate Injection, solution 98 mg/1mL Intravenous A-S Medication Solutions 2017-06-15 Not applicable US Calcium Gluconate Injection, solution 94 mg/1mL Intravenous General Injectables & Vaccines 2015-06-11 2017-07-31 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Calcium Gluconate Injection, solution 98 mg/1mL Intravenous B. Braun Medical Inc. 2023-11-02 Not applicable US Calcium Gluconate Injection, solution 98 mg/1mL Intravenous Hikma Pharmaceuticals USA Inc. 2023-11-24 Not applicable US Calcium Gluconate Injection, solution 98 mg/1mL Intravenous Somerset Therapeutics, Llc 2023-10-20 Not applicable US Calcium Gluconate Injection, solution 98 mg/1mL Intravenous Hikma Pharmaceuticals USA Inc. 2023-10-16 Not applicable US Calcium Gluconate Injection, solution 98 mg/1mL Intravenous Nivagen Pharmaceuticals, Inc. 2022-10-24 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image CALCIUM GLUCONATE INJECTION 10% Injection 940 mg/10ml Intramuscular; Intravenous B. BRAUN SINGAPORE PTE LTD 1991-08-04 Not applicable Singapore 
Calcium Gluconate Tab 600mg Tablet 600 mg Oral Swiss Herbal Remedies Ltd. 1983-12-31 2003-09-10 Canada Calcium Gluconate Tab 648mg Tablet 648 mg Oral Hall Laboratories, Ltd. 1981-12-31 2003-09-11 Canada Calcium Gluconate Tab 648mg Tablet 648 mg Oral Pharmetics (2011) Inc. 1973-12-31 2000-08-21 Canada Calcium Gluconate Tab 648mg USP Tablet 648 mg Oral Lab Gernetic Int Ltee 1985-12-31 1997-02-21 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CALCİLES 225 MG+572 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET Calcium gluconate monohydrate (225 mg/10mL) + Calcium levulinate (572 mg/10mL) Injection, solution Parenteral VEM İLAÇ SAN. VE TİC. A.Ş. 2018-03-14 Not applicable Turkey 
CALCIO AL 10% AMPOLLAS Calcium gluconate monohydrate (600 mg) + Calcium levulinate (400 mg) Solution Intravenous LABORATORIOS RYAN DE COLOMBIA S.A.S. 2008-10-07 Not applicable Colombia 
CALCİOSEL 225 mg + 572 mg / 10 mL ENJEKSIYONLUK ÇÖZELTI Calcium gluconate monohydrate (225 mg/10ml) + Calcium levulinate dihydrate (572 mg/10ml) Injection Intramuscular HAVER FARMA İLAÇ A.Ş. 2016-04-20 Not applicable Turkey Calcium "Fresenius" - Ampullen Calcium gluconate (0.95 g) + Calcium saccharate (0.036 g) Injection, solution Intravenous Fresenius Kabi Austria Gmb H 1987-09-01 Not applicable Austria 
CALCIUM GLUCONATE INJECTION USP 10% Calcium gluconate (94 mg/ml) + Calcium saccharate (4.5 mg/ml) Injection Intravenous FRESENIUS KABI (SINGAPORE) PTE LTD 1995-11-24 Not applicable Singapore - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Calcium Gluconate Calcium gluconate (94 mg/1mL) Injection, solution Intravenous Fresenius Kabi USA, LLC 2000-07-12 2016-02-29 US Calcium Gluconate Calcium gluconate (94 mg/1mL) Injection, solution Intravenous Remedy Repack 2015-06-19 2017-07-25 US Calcium Gluconate Calcium gluconate monohydrate (98 mg/1mL) Injection, solution Intravenous AMERICAN REGENT, INC. 1990-09-30 2014-01-31 US Calcium Gluconate Calcium gluconate (94 mg/1mL) Injection, solution Intravenous General Injectables & Vaccines 2015-06-11 2017-07-31 US Calcium Gluconate Calcium gluconate (94 mg/1mL) Injection, solution Intravenous A-S Medication Solutions 2000-08-09 2018-03-31 US
Categories
- ATC Codes
- A12AA03 — Calcium gluconateD11AX03 — Calcium gluconate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Sugar acids and derivatives
- Alternative Parents
- Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Monosaccharides / Secondary alcohols / Carboxylic acid salts / Polyols / Carboxylic acids / Organic calcium salts show 6 more
- Substituents
- Alcohol / Aliphatic acyclic compound / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Fatty acid / Fatty acyl / Gluconic_acid show 14 more
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- SQE6VB453K
- CAS number
- 299-28-5
- InChI Key
- NEEHYRZPVYRGPP-IYEMJOQQSA-L
- InChI
- InChI=1S/2C6H12O7.Ca/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1
- IUPAC Name
- calcium bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)
- SMILES
- [Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O
References
- General References
- Martin TJ, Kang Y, Robertson KM, Virji MA, Marquez JM: Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function. Anesthesiology. 1990 Jul;73(1):62-5. [Article]
- DRUGS.COM [Link]
- Pubchem [Link]
- ChemIDplus [Link]
- DRUGS.COM [Link]
- TITCK Product Information: Calciles (calcium gluconate/calcium levulinate) solution for injection [Link]
- External Links
- KEGG Compound
- C08133
- PubChem Compound
- 9290
- PubChem Substance
- 347827907
- ChemSpider
- 8932
- 1908
- ChEBI
- 3309
- ChEMBL
- CHEMBL2106119
- Wikipedia
- Calcium_gluconate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Prevention Hypocalcemia 1 3 Completed Diagnostic Breast Cancer / Osteoporosis 1 3 Completed Prevention Ovarian Hyperstimulation 1 3 Completed Supportive Care Chemotherapeutic Agent Toxicity / Colorectal Cancer / Neurologic toxicity / Neuropathy 1 3 Completed Supportive Care Colorectal Cancer / Neurologic toxicity 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 20 mg / mL Solution Parenteral 1.000 g Injection, solution Parenteral Solution Intravenous Injection, solution Injection Intramuscular; Intravenous 100 MG/ML Injection Intravenous Injection, solution Intravenous 0.465 meq/1mL Injection, solution Intravenous 94 mg/1mL Injection, solution Intravenous 98 mg/1mL Tablet Oral 500 mg/1 Solution Intravenous Liquid Intravenous 100 mg / mL Injection, solution Intravenous 10 mg/1mL Injection, solution Intravenous 20 mg/1mL Solution Intravenous 100 mg / mL Solution Intramuscular; Intravenous 100 mg / mL Solution Intravenous .465 mEq / mL Injection Intramuscular; Intravenous 940 mg/10ml Solution Intravenous 94 mg / mL Injection Intravenous 94 mg/ml Tablet Oral 600 mg Tablet Oral 648 mg Tablet Oral 650 mg / tab Tablet Oral 650 mg Tablet Oral 60 mg Liquid Oral Injection Intramuscular Injection, solution Parenteral 10 % Gel Topical 2.5 g/100g Powder Oral Tablet Oral Injection, solution Intravenous Liquid Intravenous 10 % / kit Solution 0.9500 g Solution Intravenous 940 mg Gel Topical 2.5 % w/w Injection Intramuscular; Intravenous 94 mg/ml Liquid Intravenous Tablet, delayed release Oral Douche Vaginal Solution 0.45 mEq/1ml Tablet, effervescent Tablet, chewable Oral 600 mg Solution 100 mg/1ml Tablet Oral 500 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US10130646 No 2018-11-20 2038-01-11 US US10342813 No 2019-07-09 2037-07-25 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 44.2 mg/mL ALOGPS logP -2 ALOGPS logP -3.4 Chemaxon logS -0.99 ALOGPS pKa (Strongest Acidic) 3.39 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 141.28 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 49.11 m3·mol-1 Chemaxon Polarizability 16.62 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 166.44838 predictedDeepCCS 1.0 (2019) [M+H]+ 168.1721 predictedDeepCCS 1.0 (2019) [M+Na]+ 174.50105 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at April 14, 2024 23:44